Innovations In Clinical Neuroscience

JAN-FEB 2018

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link:

Contents of this Issue


Page 42 of 53

R E V I E W 43 ICNS Innovations in Clinical Neuroscience • January–February 2018 • Volume 15 • Number 1–2 randomized, multicenter study. Psycho-Oncology. 2010;19:1321–1328. 29. Koppelmans V, Breteler M, Boogerd W, et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30:1080–1086. 30. Biglia N, Bounous V, Malabaila A, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care. 2012;21:485– 492. 31. Castellon S, Ganz P, Bower J, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–969. 32. Krolak D, Collins B, Weiss L, et al. Cognitive function and its relationoship to other psychosocial factors in lymphoma survivors. Support Care Cancer. 2017;25:905–913. 33. Brown P, Ballman K, Rummans T, et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol. 2006;76:283–291. 34. Osoba D, Brada M, Prados M, et al. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro Oncol. 2000;2:221–228. 35. Schagen S, Das E, Vermeulen I. Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients. Psychooncology. 2012;21:1132–1135. 36. Ahles T, Saykin A, McDonald B, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28:4434–4440. 37. Collins B, Mackenzie J, Stewart A, et al. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology. 2009;18:134–143. 38. Boykoff N, Moieni M, Subramanian S. Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009:3;223–232. 39. Lindner O, Phillips B, McCabe M, et al. A meta- analysis of cognitive impairment following adult cancer chemotherapy. Neuropsychology. 2014;28:726–740. 40. Jim H, Phillips K, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard dose chemotherapy. J Clin Oncol. 2012;30:3578–3587. 41. Tchen N, Juffs H, Downie F, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003;21:4175–4183. 42. Ganz P, Kwan L, Castellon S, et al. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst. 2013;105:791–801. 43. Ahles T, Saykin A. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7:192–201. 44. Ahles T, Root J, Ryan E. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30:3675–3686. 45. Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274–281. 46. Deprez S, Billiet T, Sunaert S, Leemans A. Diffusion tensor MRI of chemotherapy-induced cognitive impairment in non-CNS cancer patients: a review. Brain Imaging Behav. 2013;7:409–435. 47. Simo M, Rifa-Ros X, Rodriguez-Fornells A, Bruna J. Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev. 2013;37:1311–1321. 48. Shah R. Mechanistic basis of adverse drug reactions: The perils of inappropriate dose schedules. Expert Opin Drug Saf. 2005;4:103–128. 49. Sul J, DeAngelis L. Neurologic complications of cancer chemotherapy. Seminars Oncoloy. 2006;33:324–332. 50. Ahles T. Brain vulnerabilities to chemotherapy toxicities. Psychooncology. 2012;21:1141–1148. 51. Tonelli L, Postolache T, Sternberg EM. Inflammatory genes and neural activity: involvement of immune genes in synaptic function and behavior. Front Biosci. 2005;10:675– 680. 52. Tsavaris N, Kosmas C, Vadiaka M, et al. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002;87:21–27. 53. Pusztai L, Mendoza T, Reuben J, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004;25:94–102. 54. Penson R, Kronish K, Duan Z, et al. Cytokines IL-1β, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFα in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer. 2000;10:33–41. 55. Trask P, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol. 2000;18:2316–2326. 56. Scheibel R, Valentine A, O'Brien S, Meyers C. Cognitive dysfunction and depression during treatment with interferon- and chemotherapy. J Neuropsych Clin Neurosci. 2004;16:185–191. 57. Capuron L, Ravaud A, Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-α treatments in cancer patients. Psychosom Med. 2001; 63:376–386. 58. Verstappen C, Heimans J, Hoekman K, Postma T. Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs. 2003;63:1549–1563. 59. Sedletska Y, Giraud-Panis M, Malinge J. Cisplatin is a DNA-damaging antitumor compound triggering multifactorial biochemical responses in cancer cells: Importance of apoptotic pathways. Curr Med Chem Anticancer Agents. 2005;5:251–265. 60. Rolig R, McKinnon P. Linking DNA damage and neurodegeneration. Trends Neurosci. 2000;23:417–424. 61. Blasiak J, Arabski M, Krupa R, et al. Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer. Mutat Res. 2004;554:139–148. 62. Nadin S, Vargas-Roig L, Drago G, et al. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in response to chemotherapy. Cancer Lett. 2006;239:84–87. 63. Wardell T, Ferguson E, Chinnery P, et al. Changes in human mitochondrial genome after treatment of malignant disease. Mutat Res. 2003;525:19–27. 64. Weijl N, Elsendoorn T, Moison R, et al. Non-protein bound iron release during chemotherapy in cancer patients. Clin Sci. 2004;106:475–484. 65. Kaya E, Keskin L, Aydogdu I, et al. Oxidant/ antioxidant parameters and their relationship with chemotherapy in Hodgkin's lymphoma. J Int Med Res. 2005;33:687–692. 66. Papageorgiou M, Stiakaki E, Dimitriou H, et al. Cancer chemotherapy reduces plasma total antioxidant capacity in children with malignancies. Leukemia Res. 2005;29:11–16. 67. Kennedy D, Ladas E, Rheingold S, et al. Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment. Ped Blood Cancer. 2005;44:378–385. 68. Goode E, Ulrich CM, Potter J. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–1530. 69. Hung R, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: A HuGE review. Am J Epidemiol. 2005;162:925–942. 70. McDonald B, Conroy S, Ahles T, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: A prospective MRI study. Breast Cancer Res Treat. 2010;123: 819–828. 71. Kesler S, Bennett F, Mahaffery M, Spiegel D. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin Cancer Res. 2009;15:6665–6673. 72. McDonald B, Conroy S, Ahles T, et al. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol. 2012;30:2500–2508.

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - JAN-FEB 2018